| Literature DB >> 35184608 |
Zixuan Li1, Zhe Tang2, Yujie Wang1, Zijing Liu1, Senhu Wang1, Yuntao Wang1, Guozhong Wang1, Yuping Wang1, Jincheng Guo1.
Abstract
BACKGROUND: Prediabetes (PDM) and diabetes mellitus (DM) are common among acute coronary syndrome (ACS) patients. The present study evaluated the association between diabetes status and radial artery (RA) atherosclerosis using optical coherence tomography (OCT) in ACS patients.Entities:
Keywords: Diabetes; acute coronary syndrome; optical coherence tomography; prediabetes; radial artery atherosclerosis
Mesh:
Substances:
Year: 2022 PMID: 35184608 PMCID: PMC8866250 DOI: 10.1177/14791641221078108
Source DB: PubMed Journal: Diab Vasc Dis Res ISSN: 1479-1641 Impact factor: 3.291
Figure 1.Study flowchart.
Figure 2.Algorithm for radial artery OCT imaging. OCT = optical coherence tomography; RA = radial artery; RAA = radial artery angiography.
Figure 3.Representative cross-sectional optical coherence tomography images. (A) Normal RA wall shows a 3-layered architecture. (B) The microvessel (arrow) present in a patient with PDM. (C) The macrophage (arrows) present in a DM patient with long disease duration. (D) Fibrous plaque identified as a homogeneous, highly backscattering region (arrow). (E) The representative case of lipid-rich plaque. The fibrous cap thickness overlying a lipid-rich plaque was 80 μm at its thinnest part (arrow). (F) Calcified plaque identified by the presence of a well-delineated, low-backscattering heterogeneous region (asterisk). DM = diabetes mellites; NGM = normoglycemia; PDM = prediabetes.
Baseline patient characteristics.
| Variable | Overall ( | NGM ( | PDM ( | DM ( | |
|---|---|---|---|---|---|
| Age, years | 57.47±13.20 | 53.55±13.12 | 58.89±13.47
| 59.08±12.43
| 0.003 |
| Male | 264 (78.8) | 78 (83.9)c | 101 (82.1) | 85 (71.4)
| 0.047 |
| BMI, kg/m2 | 26.22±3.41 | 25.42±3.45 | 26.49±3.44 | 26.56±3.26
| 0.029 |
| Smoking | 221 (66.0) | 69 (74.2) | 81 (65.9) | 71 (59.7) | 0.086 |
| Hypertension | 179 (53.4) | 39 (41.9) | 64 (52.0) | 76 (63.9)
| 0.006 |
| Hyperlipidemia | 194 (62.0) | 50 (55.6) | 73 (64.6) | 71 (64.5) | 0.331 |
| PVD | 9 (2.7) | 2 (2.2) | 2 (1.6) | 5 (4.2) | 0.444 |
| Renal insufficiency | 18 (5.4) | 3 (3.2) | 7 (5.7) | 8 (6.7) | 0.497 |
| Prior stroke | 22 (6.6) | 7 (7.5) | 6 (4.9) | 9 (7.6) | 0.636 |
| Prior MI | 3 (0.9) | 1 (1.1) | 0 | 2 (1.7) | 0.386 |
| CAD family history | 43 (12.8) | 11 (11.8) | 16 (13.0) | 16 (13.4) | 0.938 |
| Indication for angiography | 0.266 | ||||
| STEMI | 231 (69.0) | 69 (74.2) | 88 (71.5) | 74 (62.2) | |
| NSTEMI | 66 (19.7) | 14 (15.1) | 21 (17.1) | 31 (26.1) | |
| UAP | 38 (11.3) | 10 (10.8) | 14 (11.4) | 14 (11.8) | |
| Triple vessel disease | 98 (29.3) | 25 (26.9) | 27 (22.0) | 46 (38.7)c | 0.014 |
| Multivessel disease | 212 (63.3) | 51 (54.8) | 75 (61.0) | 86 (72.3)
| 0.026 |
|
| |||||
| HbA1c, % | 6.66±1.80 | 5.42±0.02 | 5.96±0.02
| 8.34±0.20[ | <0.001 |
| Fasting glucose, mmol/L | 6.00 (5.17±7.60) | 5.14 (4.69±5.80) | 5.75 (5.24±6.5)
| 8.39 (6.45±10.74)[ | <0.001 |
| Triglycerides, mg/dL | 150.43±116.06 | 138.89±96.35 | 138.95±71.39 | 171.32±157.91 | 0.050 |
| TC, mg/dL | 177.40±41.48 | 172.82±41.57 | 183.23±41.60 | 174.95±40.93 | 0.137 |
| LDL-C, mg/dL | 116.85±34.32 | 115.13±36.53 | 121.10±34.46 | 113.79±32.17 | 0.216 |
| HDL-C, mg/dL | 42.42±13.17 | 43.70±2.12 | 42.08±8.31 | 41.78±9.51 | 0.536 |
| Lipoprotein (a), mg/L | 125 (68-261) | 109 (71,247) | 132 (71,285) | 126 (56,245) | 0.706 |
| Creatinine, μmmol/L | 75.79±15.88 | 75.41±15.62 | 77.61±15.02 | 74.20±16.87 | 0.240 |
| eGFR, mL/min/1.73 m2 | 91.77±17.41 | 95.50±17.49
| 89.70±16.52 | 90.99±17.92 | 0.044 |
| Hemoglobin, g/L | 141.33±15.96 | 142.36±17.59 | 140.52±14.32 | 141.37±16.32 | 0.704 |
|
| 0.308 | ||||
| CAG | 29 (8.7) | 11 (11.8) | 11 (8.9) | 7 (5.9) | |
| PCI | 306 (91.3) | 82 (88.2) | 112 (91.1) | 112 (94.1) | |
| Procedure time, min | 78.11±28.65 | 75.40±22.91 | 80.52±31.16 | 77.73±29.98 | 0.424 |
| Volume of CM, mL | 203.18±69.88 | 200.69±55.25 | 204.62±72.02 | 203.64±77.93 | 0.917 |
| Prior medications | |||||
| Antiplatelet | 13 (3.9) | 3 (3.2) | 4 (3.3) | 6 (5.0) | 0.772 |
| Statin | 16 (4.8) | 3 (3.2) | 4 (3.3) | 9 (7.6) | 0.224 |
| CCB | 71 (21.2) | 18 (19.4) | 23 (18.7) | 30 (25.2) | 0.407 |
| Beta blocker | 22 (6.6) | 3 (3.2) | 8 (6.5) | 11 (9.2) | 0.214 |
| ACEI/ARB | 44 (13.1) | 11 (11.8) | 14 (11.4) | 19 (16.0) | 0.520 |
| Insulin | 10 (8.4) | ||||
| Oral agents | 47 (39.5) | ||||
| Diet only | 8 (6.7) | ||||
| Newly diagnosed DM | 42 (12.5) | ||||
| Duration of DM | 7.58±5.81 | ||||
| Short (<10 years) | 78 | ||||
| Long (≥10 years) | 41 | ||||
Data are shown as mean± standard deviation, number (%), or median (interquartile range).
ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker; CAD = coronary artery disease; CAG = coronary angiogram; CCB = calcium channel blocker; DM = diabetes mellites; HDL-C = high-density lipoprotein cholesterol; LDL = low-density lipoprotein; MI = myocardial infarction; NGM = normoglycemia; PDM = prediabetes; PCI = percutaneous coronary intervention; renal insufficiency = estimated glomerular filtration <60 mL/min/1.73 m2; VD = vessel disease; SD = standard deviation.
P<0.05 for.
NGM group versus PDM group.
NGM group versus DM group.
PDM group versus DM group.
Optical coherence tomography features of the RA stratified according to glycemic status.
| Variable | Total | NGM ( | PDM ( | DM ( | |
|---|---|---|---|---|---|
| RA length
| 171.98±16.90 | 172.10±16.59 | 172.95±16.58 | 170.89±17.54 | 0.641 |
| ≥1 Plaque | 102 (30.4) | 15 (16.1) | 41 (33.3)
| 46 (38.7)
| 0.001 |
| Plaques number per patient | 1.99±1.08 | 1.50±0.82 | 1.88±1.12 | 2.26±1.06
| 0.035 |
| Total plaque length | 8.05 (4.35–17.73) | 6.6 (3.3–9.6) | 7.4 (2.95–14.65) | 8.95 (4.80–32.45) | 0.151 |
| Plaque location | |||||
| Proximal | 59 (17.6) | 7 (7.5) | 22 (17.9)
| 30 (25.2)
| 0.004 |
| Middle | 42 (12.5) | 6 (6.5) | 6 (13.0) | 20 (16.8)
| 0.076 |
| Distal | 71 (21.2) | 9 (9.7) | 26 (21.1)
| 36 (30.3)
| 0.001 |
| Fibrous plaque | 68 (20.3) | 11 (11.8) | 28 (22.8) | 29 (24.4) | 0.055 |
| Total length | 5.30 (2.73–9.40) | 4.9 (3.0–9.6) | 5.20 (2.18–7.95) | 5.6 (2.8–17.65) | 0.564 |
| Lipid plaque | 47 (14.0) | 6 (6.5) | 18 (14.6) | 23 (19.3)
| 0.027 |
| Total length | 5.60 (3.20–10.80) | 5.05 (2.68–8.55) | 5.7 (4.4–14.3) | 4.8 (3.2–10.8) | 0.504 |
| Calcified plaque | 23 (6.9) | 1 (1.1) | 8 (6.5) | 14 (11.8)
| 0.009 |
| Total length | 9.8 (5.9–35.0) | 2.9 | 9.05 (6.50–47.95) | 10.70 (4.83–39.83) | 0.375 |
| Micro vessels | 122 (36.4) | 22 (23.7) | 48 (39.0)
| 52 (42.7)
| 0.008 |
| Macrophages | 43 (12.8) | 8 (8.6) | 15 (12.2) | 20 (16.8) | 0.201 |
|
| |||||
| Lumen area, mm2 | 6.22 (5.00–8.00) | 6.15 (4.52–7.78) | 6.58 (5.11–8.13) | 5.94 (4.90–8.11) | 0.332 |
| Diameter, mm | 2.80 (2.52–3.18) | 2.78 (2.43–3.11) | 2.86 (2.54–3.21) | 2.75 (2.52–3.21) | 0.242 |
| Maximal intimal thickness, mm | 0.13 (0.08–0.17) | 0.10 (0.06–0.14) | 0.13 (0.08–0.18)
| 0.15 (0.10–0.19)
| <0.001 |
| IMR | 0.90 (0.53–1.40) | 0.75 (0.37–1.20) | 0.91 (0.53–1.27) | 1.10 (0.65–1.63)
| 0.001 |
| IEI | 2.65 (1.87–3.25) | 2.19 (1.67–2.92) | 2.72 (1.83–3.24)
| 2.84 (2.17–3.44)
| <0.001 |
| ITI | 0.46 (0.37–0.57) | 0.43 (0.36–0.50) | 0.46 (0.37–0.58) | 0.49 (0.38–0.60) | 0.217 |
| LN, % | 26.95 (23.92–30.45) | 26.11 (23.48–29.67) | 27.26 (24.22–30.39) | 27.56 (23.92–31.32) | 0.622 |
| Intima area, mm2 | 0.72 (0.55–0.93) | 0.63 (0.49–0.85) | 0.74 (0.58–0.95)
| 0.76 (0.59–0.96)
| 0.005 |
| Media area, mm2 | 1.60 (1.32–1.91) | 1.54 (1.23–1.92) | 1.64 (1.36–1.91) | 1.62 (1.36–1.91) | 0.790 |
| Crescent-shaped intimal hyperplasia | 53 (15.8) | 8 (8.6) | 19 (15.4) | 26 (21.8)
| 0.032 |
IMR = intima-media ratio; IEI = intimal eccentricity index; ITI = intimal thickness index; LN = luminal narrowing.
Distance from RA ostium to puncture site;
p < 0.05 for NGM group versus PDM group;
p < 0.05 for NGM group versus DM group
Subgroup analysis of DM (n = 119)
| Variable | DM duration <10 years (n = 78) | DM duration ≥10 years (n = 41) | |
|---|---|---|---|
| Presence of plaque | 21(26.9) | 25(61.0) | <0.001 |
| Plaque site | |||
| Proximal | 13(16.7) | 17(41.5) | 0.003 |
| Middle | 7(9.0) | 13(31.7) | 0.002 |
| Distal | 15(19.2) | 21(51.2) | <0.001 |
| Total length | 7.90(4.80–13.30) | 13.10(4.80–36.65) | 0.270 |
| Fibrous | 14(17.9) | 15(36.6) | 0.024 |
| Total length | 4.9(2.85–8.65) | 6.60(2.30–26.50) | 0.541 |
| Lipid | 10(12.8) | 13(31.7) | 0.013 |
| Total length | 4.85(3.05–14.45) | 4.80(2.90–11.60) | 0.877 |
| Calcification | 5(6.4) | 9(22.0) | 0.028 |
| Total length | 10.10(6.10–51.45) | 13.40(5.65–44.65) | 0.841 |
| Micro vessels | 32(41.0) | 20(48.8) | 0.418 |
| Macrophages | 9(11.5) | 11(26.8) | 0.034 |
| Crescent-shaped intimal hyperplasia | 18(23.1) | 8(19.5) | 0.655 |
Logistic regression analysis of RA plaque
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| OR | 95%CI | OR | 95%CI | |||
|
| ||||||
| Age, years | <0.001 | 1.086 | 1.061–1.111 | <0.001 | 1.087 | 1.053–1.122 |
| HbA1c, % | 0.029 | 1.148 | 1.014–1.299 | 0.007 | 1.221 | 1.056–1.411 |
| | ||||||
| Age, years | <0.001 | 1.093 | 1.050–1.137 | <0.001 | 1.099 | 1.043–1.159 |
| DM Duration (long | <0.001 | 4.241 | 1.901–9.463 | 0.005 | 3.752 | 1.502–9.369 |
aadjustment for age, sex, hypertension, eGFR, HbA1c, triglycerides, statin, and antiplatelet.
badjustment for age, DM duration, eGFR, hypertension, and triglycerides.
Figure 4.Receiver-operating characteristic curves of HbA1c combined with age for predicting RA plaque presence.
Linear regression analysis of RA intimal hyperplasia
| Variable | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| β | 95% CI for β | β | 95% CI for β | |||
|
| ||||||
| Age, years | 0.031 | <0.001 | 0.024–0.039 | 0.413 | <0.001 | 0.024–0.039 |
| HbA1c, % | 0.143 | 0.009 | 0.020–0.138 | 0.135 | 0.007 | 0.021–0.128 |
|
| ||||||
| Age, years | 0.541 | <0.001 | 0.024–0.034 | 0.491 | <0.001 | 0.021–0.032 |
| Sex | −0.317 | <0.001 | −0.731–0.375 | −0.131 | 0.009 | −0.397–0.058 |
aadjustment for sex, smoker, BMI, eGFR, hypertension, familial history of CAD, lipid levels, cholesterol, and medications.
badjustment for smoker, BMI, eGFR, HbA1c, hypertension, familial history of CAD, lipid levels, cholesterol, and medications.